Clinical Trial Update: Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating secukinumab for psoriasis in adult Turkish patients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriasis | Phase 3 | Status: WITHDRAWN